CG Oncology, Inc. Common stock

CGONNASDAQHealthcare● Active

$54.40

+$0.68(+1.27%)

Market Cap$4.8B

P/E Ratio—

52W High$75.5

52W Low$23.65

Avg Volume1.2M

Open$55.06

Beta0.31

Free Cash Flow Financials Revenue

CG Oncology, Inc. Common stock (CGON) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CGON · free cash flow · updated Jun 8, 2026

Core FCF metrics

CGON · FCF · TTM · margin & CAGR

Free cash flow was −$132.5M for FY2025 (fiscal year ending 2025-12-31), down 67.8% year-over-year

FY2025 Free Cash Flow−$132.5M▼ -67.8% YoY

Trailing 12M (TTM)−$160.4Mtrailing 4 quarters sum

FCF Margin< −999%−$132.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CGON · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$132.3M(0M)−$132.5M▼ 67.8%—

FY2024−$78.7M(0M)−$78.9M▼ 72.8%—

FY2023−$45.7M(0M)−$45.7M▼ 53.2%—

FY2022−$29.8M(0M)−$29.8M▼ 116.8%—

FY2021−$13.7M(0M)−$13.8M—-132.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CGON · P/FCF · FCF yield · FCF per share

CG Oncology, Inc. Common stock (CGON) reported negative free cash flow of −$0.13B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CGON · cash flow statement · operating / investing / financing

For FY2025, CG Oncology, Inc. Common stock generated −$132.3M in operating cash flow and spent 0M in capital expenditures, yielding −$132.5M in free cash flow.

Operating Activities

−$132.3M

Cash from core business operations

2025-12-31

Investing Activities

−$245.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$153.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$132.3M) − |CapEx| (0M) = FCF (−$132.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CGON vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

CG Oncology, Inc. Common stockYOU

CGON

−$132.5M-67.8%-3279.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

CG Oncology, Inc. Common stock (CGON) reported free cash flow of −$132.5M for FY2025 (fiscal year ending 2025-12-31), down 67.8% year-over-year.

CG Oncology, Inc. Common stock has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 5 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CGON free cash flow · 8 questions

CG Oncology, Inc. Common stock free cash flow was −$132.5M for FY2025, down 67.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$160.4M.

CGON free cash flowCGON FCFCGON FCF 2025CGON free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · CG Oncology, Inc. Common stock · CG Oncology, Inc. Common stock SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026